These statements should encourage the scientists into developing more targeted treatments for COVID-19 survivors; we hope that new strategies of upregulating the levels of ACE2/Ang 1-7/MasR axis could prevent instalment of severe long-term consequences of the virus, or at least improve the quality of life for the already diagnosed patients several months post-infection. This evidence concerns the gene ANGPT1 and COVID-19.